GLP-1 Tablets UK 2026: The Wegovy Pill, Doses & Results

For years the question came up in almost every consultation. "Is there a version I can just swallow?" And for years the honest answer was no, not for weight loss. That changed in June 2026, when the MHRA approved the first GLP-1 tablet for weight management in the UK.

So if you have been searching for GLP-1 tablets, here is where things actually stand: one is licensed, one is coming, and a great many products marketed online as "GLP-1 pills" are neither.

What counts as a GLP-1 tablet in the UK?

A GLP-1 medicine works by copying a hormone your gut releases after you eat. It acts on the appetite centres in your brain, so you feel full sooner, stay full longer, and think about food less. If you want the mechanism in more depth, we have written a full explainer on how GLP-1s work.

Until this year, every GLP-1 licensed for weight loss in the UK came in a pen. Wegovy, Mounjaro, Saxenda. All injections.

Now there is one tablet: Wegovy tablets, which contain semaglutide, the same active ingredient as the Wegovy injection. That is the whole list. One product, one licence.

Two other names come up constantly in searches, and both need clearing up.

Rybelsus is also oral semaglutide, and it has been available in the UK for a while. But it is licensed for type 2 diabetes only, not for weight loss. Different licence, different dosing, different purpose.

Orforglipron (brand name Foundayo) is a genuinely new kind of oral GLP-1, made by Eli Lilly. It was approved in the United States in April 2026. As of July 2026 it has no UK licence, so no legitimate UK pharmacy can dispense it. We cover the detail in our guide to orforglipron in the UK.

Anything else sold as a "GLP-1 tablet", "GLP-1 supplement" or "GLP-1 capsule" over the counter, in a health shop or on a marketplace site, is not a GLP-1 medicine. It cannot be. These are prescription-only medications, and the same rule applies to the patches and drops that have flooded social media.

The Wegovy tablet: what the MHRA actually approved

On 11 June 2026 the MHRA approved the semaglutide tablet for weight loss and weight management in adults, alongside a reduced-calorie diet and more physical activity. The European Medicines Agency's expert committee had recommended the same change for the EU a few weeks earlier, in May.

You may be eligible if you have:

• A BMI of 30 or above, or
• A BMI between 27 and 30 with at least one weight-related health condition, such as high blood pressure, sleep apnoea or type 2 diabetes

That is the same threshold used for the injections, and it is the same threshold we use at heySlim. A clinician still has to assess you first. There is no version of this where you simply order it.

The dosing schedule

The tablet builds up slowly, exactly as the pens do. According to the patient information leaflet, you stay at each step for a month before moving up.

Four months from starting to reaching the full dose. If side effects are troubling you, a clinician can hold you at a lower step for longer, which is often the right call. Taking two tablets to "catch up" a higher dose is not, and the leaflet says so explicitly.

One detail worth knowing if you are already on the injection: the MHRA guidance says people currently treated privately with a 2.4 mg weekly semaglutide injection can move straight to 25 mg tablets daily, without starting again at the bottom.

Do GLP-1 tablets actually work?

This is the question that matters, and it has a proper answer rather than a marketing one.

The tablet was tested in a phase 3 trial called OASIS 4, published in the New England Journal of Medicine. 307 adults with overweight or obesity, no diabetes, randomly assigned to either oral semaglutide 25 mg or placebo, plus lifestyle support, for 64 weeks of treatment.

Average weight change at week 64: 13.6% with the tablet, against 2.2% with placebo. Around 30% of people on the tablet lost at least a fifth of their body weight. On placebo, 3% did.

For context, that result sits close to what the 2.4 mg weekly semaglutide injection achieved in its own pivotal trial. Same molecule, different delivery, broadly similar outcome.

What the tablet does not do is beat tirzepatide. Mounjaro still produces the largest average weight loss of any licensed option in the UK, and if you want the head-to-head we have compared them in Wegovy vs Mounjaro.

Worth being clear about what that means. The tablet is the same medicine without the needle, roughly as effective, no more. For some people that is still the difference between starting treatment and never starting at all.

The bit people get wrong: how you have to take it

Semaglutide is a large, fragile molecule. Getting it to survive your stomach and reach your bloodstream takes some doing, which is why the tablet comes with rules the injection never had.

Every morning:

• Take it after fasting for at least 8 hours, so first thing on waking
• Swallow it whole with a sip of plain water, no more than 120 ml
• Do not split, crush or chew it
• Wait at least 30 minutes before eating, drinking anything else, or taking any other tablets

Thirty minutes. Not ten. Coffee counts. Your levothyroxine counts.

Which is worth thinking honestly about before you choose. A weekly pen asks something of you once every seven days. A tablet asks something of you every single morning, before coffee, for as long as you are on it.

Side effects, and who should not take it

The side-effect profile is recognisably GLP-1. Most of it is gastrointestinal, most of it is worst in the first weeks and after each dose increase, and most of it settles.

The patient leaflet lists these as very common, meaning more than 1 in 10 people:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Stomach pain
• Headache
• Feeling weak or tired
• Indigestion

In the OASIS 4 trial, gastrointestinal side effects affected 74% of people on the tablet compared with 42% on placebo, and were mostly mild to moderate. Notably, only 7% of people stopped treatment because of side effects, against 6% on placebo. Unpleasant, then, but rarely a reason to quit. Our guidance on managing Mounjaro's side effects applies almost entirely here too.

Rarer but serious problems are the same ones we watch for with every GLP-1: pancreatitis, gallstones, and a very rare eye condition called NAION. Sudden or rapidly worsening vision, or severe stomach pain that will not go away, means stopping the medicine and getting seen the same day.

The tablet is not for you if you are pregnant, trying to conceive, or breastfeeding. It is not licensed under 18. And tell your clinician if you take levothyroxine or warfarin, because both may need monitoring. It also carries a black triangle, which means the MHRA is collecting extra safety data on it. That is routine for a new medicine, not a warning sign.

What do GLP-1 tablets cost in the UK?

Not on the NHS. The MHRA press release is explicit: the tablet is approved for use but is not currently available on the NHS, and any NHS decision will follow a NICE evaluation. So for now it is a private prescription.

At the time of writing, UK online pharmacies were listing the 1.5 mg starting dose from around £99 a month, with the 25 mg maintenance dose typically landing somewhere between £180 and £250. That is broadly in line with what people pay for the Wegovy injection, so if you were hoping the tablet would be the cheap option, it is not. Our Wegovy price guide tracks how those figures move.

One thing worth watching: headline prices often apply to the first month, or to a six or twelve-month commitment. Price the maintenance dose, not the starter, because that is what you will actually be paying from month four.

Tablet or injection: how to think about the choice

There is no clinically correct answer here, and that is quite freeing once it sinks in. Both work. The right one is the one you will still be taking in eight months.

A tablet tends to suit you if needles are a real barrier rather than a mild dislike, if you already have a fixed morning routine, and if a strict fasting window sounds like structure rather than a burden.

An injection tends to suit you if mornings are unpredictable, if you would rather think about your medication once a week than seven times, or if you want tirzepatide specifically, which only exists as an injection and always will. Tirzepatide is broken down too quickly in the gut for a tablet version to be viable.

And one thing that does not change with the format: stopping the medicine brings appetite back. Weight regain after stopping is common with every GLP-1, tablet or pen, which is why we talk about maintenance from the beginning rather than at the end. We have written about what happens when you stop in more detail.

Beware what gets sold as a "GLP-1 pill"

Search "GLP-1 tablets" and you will see supplements from high-street health shops sitting alongside the real thing. Berberine capsules. "GLP-1 boosters." Fibre blends promising to "activate your natural GLP-1".

None of these are GLP-1 receptor agonists. They cannot be sold over the counter, because every GLP-1 medicine in the UK is prescription-only, and the MHRA has been clear about that. Some are harmless. Some are not. A few sites will happily sell you unlicensed orforglipron right now, which means whatever arrives in the post is unregulated at best.

If you want the honest survey of what does and does not work in a capsule, we have it in weight loss pills in the UK.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.